Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 53

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 53
---
 following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner
were unaware during prosecution. These assertions may also be based on information known to us or the USPTO. If a defendant were to prevail
on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent rights directed towards
the applicable drug candidates or technology related to the patent rendered invalid or unenforceable. Such a loss of patent rights would
materially harm our business, financial condition, results of operations and prospects.

Interference proceedings provoked by third parties
or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent
applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from
the prevailing party. Our business could be materially harmed if the prevailing party does not offer us a license on commercially reasonable
terms or at all.

Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation.

The pharmaceutical industry is characterized by
extensive litigation regarding patents and other intellectual property rights. Moreover, the cost to us of any litigation or other proceeding
relating to our patents and other intellectual property rights, even if resolved in our favor, could be substantial, and the litigation
would divert our management’s efforts. We may not have sufficient resources to bring any such action to a successful conclusion.
Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations and
you could lose all of your investment.

Some of our competitors are larger than we are
and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or
proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property
portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise
violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property
claims could result in substantial costs and diversion of management resources, which could harm our business. In